Describe dicyclomimme on the basisi 9f pharmacology of veterinary science
Reading File
Finding Sources
Searching the Web
dicyclomine veterinary pharmacology uses mechanism antispasmodic animals
Reading File
Finding Sources
I now have sufficient information to give a thorough answer. Here is a complete pharmacological description of dicyclomine with veterinary relevance:
Dicyclomine - Veterinary Pharmacology
1. Drug Identity
Dicyclomine (also spelled dicycloverine; brand names include Bentyl, Merbentyl) is a synthetic tertiary amine anticholinergic/antispasmodic agent. Its chemical name is 2-(diethylamino)ethyl bicyclohexyl-1-carboxylate hydrochloride (molecular formula C₁₉H₃₅NO₂·HCl; MW 345.95). It belongs to the same pharmacological class as atropine and hyoscine but with a distinctly different potency and receptor selectivity profile - classified as a Synthetic Tertiary Amine Antimuscarinic Compound alongside thiphenamil and cyclopentolate (Barash's Clinical Anesthesia, 9e).
2. Classification
| Property | Detail |
|---|---|
| Drug class | Anticholinergic / Antispasmodic |
| Sub-class | Synthetic tertiary amine antimuscarinic |
| Receptor target | Muscarinic acetylcholine receptors (M1, M2, M3) |
| Primary action site | Gastrointestinal smooth muscle |
3. Mechanism of Action (Dual Mechanism)
Dicyclomine acts through two distinct and complementary mechanisms - this is what makes it superior to purely anticholinergic drugs for GI spasm:
A. Anticholinergic (Antimuscarinic) Effect
- Competitively blocks muscarinic acetylcholine (ACh) receptors on GI smooth muscle
- Prevents ACh from binding, thereby reducing parasympathetic-driven smooth muscle contraction
- Potency approximately 1/8th that of atropine at muscarinic receptors (tested in vitro in guinea pig ileum)
- Much weaker than atropine on non-GI muscarinic sites:
- ~1/500th the mydriatic potency of atropine (mice)
- ~1/300th the antisialagogue potency of atropine (rabbits)
- This selective GI targeting makes it more suitable in veterinary use with fewer systemic side effects
B. Direct Musculotropic (Papaverine-like) Effect
- Directly relaxes GI smooth muscle independent of autonomic innervation
- Antagonizes spasms induced by bradykinin and histamine - agonists that atropine cannot block
- Equally potent against ACh-induced and barium chloride (BaCl₂)-induced intestinal spasm, while atropine is 200x more potent against ACh than BaCl₂
- This musculotropic effect is especially valuable in animals with non-cholinergic GI spasms
This dual profile is pharmacologically significant: it covers both neurogenic and non-neurogenic spasm, broadening therapeutic utility.
4. Veterinary Uses
Though primarily a human GI drug, dicyclomine has documented animal pharmacology and veterinary applications:
Gastrointestinal Antispasmodic
- Treatment of intestinal colic, spasm, and cramping in dogs, cats, and occasionally horses
- Reduces excessive GI motility in irritable bowel syndrome (IBS) equivalents in small animals
- Used in IBS-D (diarrhea-predominant) patterns - decreases GI spasms and motility
- Adjunct in acute gastroenteritis with cramping
Urogenital Tract Spasm
- Relieves smooth muscle spasm of the urinary tract (ureteral or bladder spasm)
Biliary Spasm
- Occasional use in biliary colic involving smooth muscle of bile ducts
Pain Relief (Indirect)
- Reduction of GI spasm alleviates associated pain - useful post-operatively or in colic episodes
5. Pharmacokinetics (Animal and Human Data)
| Parameter | Details |
|---|---|
| Administration routes | Oral (tablet, suspension), Intramuscular injection |
| Absorption | Well absorbed orally; peak plasma ~60-90 min after oral dose |
| Distribution | Widely distributed; crosses blood-brain barrier poorly (tertiary amine) |
| Metabolism | Hepatic |
| Elimination | Biliary and renal; half-life ~1.8 hrs (initial), ~9-10 hrs (secondary) |
| Protein binding | Moderate |
Unlike quaternary ammonium antimuscarinics (e.g., glycopyrrolate), dicyclomine's tertiary amine structure allows it to cross the BBB to a limited extent, contributing to its mild CNS effects.
6. Pharmacological Comparison with Atropine (Key Veterinary Drug)
| Feature | Dicyclomine | Atropine |
|---|---|---|
| Receptor | Muscarinic (competitive block) | Muscarinic (competitive block) |
| Musculotropic effect | Yes (direct on smooth muscle) | No |
| Antisecretory potency | ~1/300th | Strong |
| Mydriatic potency | ~1/500th | Strong |
| Heart rate effect | Mild tachycardia | Marked tachycardia |
| GI spasm selectivity | High | Moderate |
| CNS penetration | Limited | Yes |
Dicyclomine is preferred over atropine when GI-selective action is needed without significant cardiovascular or ophthalmic side effects in veterinary patients.
7. Adverse Effects
In veterinary patients (extrapolated from animal studies and clinical use):
- Anticholinergic effects: dry mouth (xerostomia), reduced salivation, constipation
- CNS effects: mild sedation, restlessness (rare, due to limited BBB penetration)
- Cardiovascular: mild tachycardia (much less than atropine)
- Urinary retention: especially in male animals with prostatic disease
- GI stasis: at high doses; risk of paralytic ileus
- Hyperthermia: reduced sweating (relevant in active or working animals)
- Blurred vision / cycloplegia: very rare at therapeutic doses
8. Contraindications in Veterinary Practice
- Glaucoma (all types) - blocks pupillary constriction and elevates intraocular pressure
- Obstructive GI disease (paralytic ileus, pyloric stenosis) - further impairs motility
- Obstructive uropathy - worsens urinary retention
- Myasthenia gravis - anticholinergic drugs worsen neuromuscular junction dysfunction
- Cardiac arrhythmias / tachycardia - even mild tachycardia is undesirable
- Megacolon in cats - smooth muscle relaxation worsens fecal retention
- Pregnancy - antispasmodic medications are generally avoided in pregnant animals as safety is unestablished (Yamada's Textbook of Gastroenterology, 7e)
9. Drug Interactions
- Other anticholinergics (atropine, glycopyrrolate): additive antimuscarinic toxicity
- Antacids: may reduce oral absorption of dicyclomine
- Antiglaucoma agents (pilocarpine, timolol): dicyclomine antagonizes their miotic effects
- Phenothiazines, antihistamines, tricyclic antidepressants: enhanced anticholinergic effects
- GI prokinetics (metoclopramide, cisapride): pharmacological antagonism - concurrent use is counterproductive
10. Available Formulations and Doses
| Formulation | Details |
|---|---|
| Oral tablets | 10 mg, 20 mg |
| Oral solution | 10 mg/5 mL |
| Injection (IM only) | 10 mg/mL |
Note: IV administration is contraindicated - causes serious adverse reactions including cardiovascular collapse in animals.
Veterinary dosing is generally extrapolated from human guidelines (0.15-0.3 mg/kg orally 2-3 times daily in dogs) with dose adjustments based on species and body weight. Always consult current formularies for species-specific dosing.
11. Summary
Dicyclomine is a synthetic antispasmodic agent with a unique dual mechanism - anticholinergic (antimuscarinic, ~1/8th atropine potency) plus direct musculotropic smooth muscle relaxation. In veterinary science, its primary value is in treating GI smooth muscle spasms in small animals, with a favorable safety profile compared to atropine due to minimal effects on heart rate, salivation, and vision. Its ability to antagonize both cholinergic and non-cholinergic (bradykinin, histamine) spasm gives it broader utility than purely antimuscarinic drugs.
Sources: Barash's Clinical Anesthesia, 9e (Classification); Yamada's Textbook of Gastroenterology, 7e (Antispasmodics); Lippincott Illustrated Reviews: Pharmacology (IBS use); DailyMed prescribing information (mechanism); RIVA-Dicyclomine monograph (animal pharmacology data).
This is a shared conversation. Sign in to Orris to start your own chat.